Observing simplified HIV treatment in China

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the efficacy and safety of a simplified therapy regimen for HIV-1 infected patients in a real-world setting in China. A total of 600 participants will receive a combination of lopinavir/ritonavir and lamivudine over a 36-month period. The study will monitor viral inhibition rates, changes in CD4 cell counts, safety, and patient compliance through follow-ups at 12, 24, and 36 months. The approach focuses on simplifying treatment to improve adherence and outcomes for patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. HIV-1 infection confirmed
2. Agree to use simplified therapy regimen.
3. Agree to detect CD4 count at least once per half a year

Exclusion Criteria:

1. Have participated in HIV vaccine clinical trial or other drug trials in the past three months.
2. Patients who could not complete the scheduled follow-up (such as weakness and poor compliance).
3. Patients who have the history of resistance or allergy to LPV/r or 3TC.

Where it's running

• Guangzhou 8th People's Hospital
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Linghua Li, Doctor
• Email: llheliza@126.com
• Phone: 020-83710825

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Peer-led Dynamic Choice HIV Prevention for Women

  This trial tests a peer-led HIV prevention approach to see if it helps women at higher risk in Uganda better prevent HIV than standard care.

  Recruiting University of California, San Francisco · Kampala · NCT07787988

• Improving long-term medication adherence for HIV treatment

  This study is testing whether daily text messages and rewards can help people starting HIV treatment stick to their medication plan over the long term.

  Recruiting Rand · Kampala · NCT06949774

• Using a mobile app to reduce HIV infections in young men and non-binary individuals

  This study is testing a mobile app designed to help young men and non-binary individuals reduce their risk of getting HIV.

  Recruiting at 2 sites Columbia University · Chicago, Illinois and 1 other locations · NCT06741631

• Mobile intervention for HIV prevention in young men who have sex with men

  This study is testing a mobile program that helps young men who have sex with men learn about and access HIV prevention methods, like PrEP, to see if it can reduce their risk of getting HIV.

  Recruiting Columbia University · New York, New York · NCT06741618

• A program to improve PrEP use among young women in Kenya

  This study is testing a new program to help young women in Kenya use HIV prevention medication more effectively by providing support and resources tailored to their needs.

  Recruiting Massachusetts General Hospital · Kisumu · NCT06566430

• Using a pill sensor system to improve HIV treatment adherence

  This study is testing a new pill sensor system to see if it helps adults with HIV stick to their treatment better and improve their health.

  Recruiting Phase 2 University of California, Los Angeles · Los Angeles, California · NCT06480578

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.